Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine with PD-1 Inhibitor and Radiotherapy in Advanced NSCLC
NCT06751901Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Objective Response Rate at 30 weeks, Disease Control Rate at 30 weeks and 1 more. Started Mar 2024; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06751901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751901.